Research Library / Melanocortin / Afamelanotide
Melanocortin researchAfamelanotide (MT1)
Scenesse · Melanotan I · MT-I
An α-MSH analog that increases eumelanin production. The listed community example (community loading schedule) describes 0.5–1 mg per administration, once daily for 1–2 weeks, via subcutaneous; this is not a validated dosing recommendation. An illustrative 10 mg vial at an assumed 2 mL final volume yields 5 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 10mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 5mg/mL · conditional arithmetic
- One U-100 marking
- 50mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
16 mg implant · administered every 2 months
Adults with erythropoietic protoporphyriaFDA label| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Community loading schedule | 0.5–1 mg | 0.5–1 mg/day | Once daily for 1–2 weeks | Consistent daily time | Subcutaneous | Community-reported |
| Community maintenance schedule | 0.5–1 mg | 1–3 mg/week | Two or three times weekly | Evenly spaced | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
20 example portions per vial
20 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
0.5 mg community example · 5 mg/mL · 0.1 mL · 10 units
Community-vial arithmetic only: 1 mg equals 0.20 mL (20 U-100 units). This must not be confused with SCENESSE, the regulated 16 mg controlled-release implant administered by a trained professional. SCENESSE is a controlled-release implant, distinct from the 10 mg research-powder example. Implant labeling does not validate powder-vial reconstitution. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
10 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · Community loading schedule
Vial counts and final solution totals below use the selected 10 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 0.5–1 mg | Once daily for 1–2 weeks | 3.5–7 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 14–28 mg | 2–3 × 10 mg |
| 8 weeks | 28–56 mg | 3–6 × 10 mg |
| 12 weeks | 42–84 mg | 5–9 × 10 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 4–6 mL | Not established |
| 8 weeks | 6–12 mL | Not established |
| 12 weeks | 10–18 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 28 |
| 8 weeks | 56 |
| 12 weeks | 84 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 10–20 administrations
8 weeks: 10–20 administrations
12 weeks: 10–20 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Afamelanotide · Scenesse · Melanotan I · MT-I
- Evidence / status
- FDA approved. FDA approved for erythropoietic protoporphyria
- Clinical route, frequency & duration
Approved-product program: 16 mg implant · administered every 2 months
- Community purpose
- Pigmentation, tanning, and photoprotection research.
Community-reported loading phase
Initial phase: 1–2 weeks
Pattern: 0.5–1 mg once daily
Transition: Then 0.5–1 mg two or three times weekly
This describes community use of research-vial MT1. It is not interchangeable with the regulated 16 mg controlled-release afamelanotide implant.
Reconstitution & formulation
SCENESSE is a controlled-release implant, distinct from the 10 mg research-powder example. Implant labeling does not validate powder-vial reconstitution.
Other vehicles and approaches discussed
No compulsory alternate solvent was established for generic powder. The calculation assumes a known final volume and a verified product identity.
- Evidence context
- No new alternate-solvent requirement established
- Cloudiness / gel signal
- Implant versus unapproved powder distinction
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Implant versus unapproved powder distinction
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Melanocortin-1 receptor agonist
An α-MSH analog that increases eumelanin production. Approval applies to a specific implant and indication.
Community-reported purpose
Pigmentation, tanning, and photoprotection research.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Approved-product program
Protocol: 16 mg implant · administered every 2 months
Population: Adults with erythropoietic protoporphyria
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Labeling describes implant-site reactions and pigmentation changes; approval does not extend to unapproved tanning products.
Development and regulatory status
FDA approved for erythropoietic protoporphyria
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Afamelanotide?
An α-MSH analog that increases eumelanin production. Approval applies to a specific implant and indication.
Melanocortin-1 receptor agonist
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
Community-reported loading phase: 1–2 weeks. This describes community use of research-vial MT1. It is not interchangeable with the regulated 16 mg controlled-release afamelanotide implant.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
SCENESSE is a controlled-release implant, distinct from the 10 mg research-powder example. Implant labeling does not validate powder-vial reconstitution.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeFDA label: Approved-product program
- Product labelSCENESSE product label
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.